Thursday, September 24, 2020 3:33:30 PM
"The mice develop a similar lung disease to what we see in humans," said Diamond, who is also a professor of molecular microbiology, and of pathology and immunology. "They get quite sick for a while but eventually recover, like the vast majority of people who get COVID-19. You can use this technique with almost any strain of laboratory mouse to make them susceptible to SARS-CoV-2 and then do whatever kind of study you want: test vaccines or drugs, study the immune response, and many other things related to how the virus causes disease."
https://medicalxpress.com/news/2020-06-covid-mouse-drugs-vaccines.html
A mouse model study was conducted to assess systemic IgG and mucosal IgA antibody production against S1 Ag after intranasal vaccination with MediciNova’s BC-PIV SARS-CoV-2 vaccine prototype. We confirmed a high IgA antibody titer against S1 Ag in the nasal lavage fluid from mice given intranasal BC-PIV SARS-CoV-2 vaccine. We also confirmed that a high IgG antibody titer against S1 Ag was induced in mice serum.
Yuichi Iwaki, M.D., Ph.D., President and Chief Executive Officer of MediciNova, Inc., commented, "We are very encouraged that our intranasal BC-PIV SARS-CoV-2 vaccine induced high titers of systemic serum IgG and mucosal IgA neutralizing antibodies in a mouse model study. These successful results support the scientific and technical rationale of our intranasal vaccine in addition to similar success with BioComo’s BC-PIV RSV vaccine prototype. We look forward to reporting additional progress on our intranasal COVID-19 vaccine in the near future.”
https://finance.yahoo.com/news/medicinova-announces-intranasal-covid-19-103000673.html
Recent MNOV News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:29 PM
- MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) • GlobeNewswire Inc. • 04/02/2024 11:00:00 PM
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan • GlobeNewswire Inc. • 03/26/2024 11:00:00 PM
- MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society • GlobeNewswire Inc. • 03/20/2024 11:00:00 PM
- MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology • GlobeNewswire Inc. • 03/12/2024 10:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 09:25:31 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:27:28 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:25:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:23:50 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:21:57 PM
- MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China • GlobeNewswire Inc. • 01/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:52:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:52:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 09:51:33 PM
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology • GlobeNewswire Inc. • 12/21/2023 11:00:00 PM
- MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe • GlobeNewswire Inc. • 12/06/2023 11:00:00 PM
- Stocks Set to Open Higher as Investors Await FOMC Minutes and Nvidia Earnings • IH Market News • 11/20/2023 12:42:19 PM
- MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology • GlobeNewswire Inc. • 11/19/2023 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:15:31 PM
- MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria • GlobeNewswire Inc. • 10/27/2023 05:00:00 AM
- MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada • GlobeNewswire Inc. • 10/10/2023 11:00:00 PM
- MediciNova Receives Gene Therapy Milestone Payment • GlobeNewswire Inc. • 10/04/2023 11:00:00 PM
- MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury • GlobeNewswire Inc. • 09/27/2023 11:00:00 PM
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology • GlobeNewswire Inc. • 08/17/2023 11:00:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM